AG-920 for Anesthesia, Local

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
American Genomics Site 2, McAllen, TX
Anesthesia, Local+1 More
AG-920 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

A Phase 3, randomized, placebo-controlled, double-masked, parallel study in healthy subjects. It is designed to evaluate the ocular safety of a single topical ocular administration of AG-920 sterile topical ophthalmic solution compared to placebo..

Eligible Conditions

  • Anesthesia, Local

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Anesthesia, Local

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: From randomization through study completion (up to 4 days following treatment); 90 days following treatment for subjects participating in specular microscopy.

Day 90
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Day 90
Mean change from baseline in corneal endothelial cell density after treatment with AG-920

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Anesthesia, Local

Trial Design

2 Treatment Groups

AG-920
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

240 Total Participants · 2 Treatment Groups

Primary Treatment: AG-920 · Has Placebo Group · Phase 3

AG-920
Drug
Experimental Group · 1 Intervention: AG-920 · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AG-920
2020
Completed Phase 3
~260

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from randomization through study completion (up to 4 days following treatment); 90 days following treatment for subjects participating in specular microscopy.
Closest Location: American Genomics Site 2 · McAllen, TX
Photo of texas 1Photo of texas 2Photo of texas 3
2021First Recorded Clinical Trial
3 TrialsResearching Anesthesia, Local
1 CompletedClinical Trials

Who is running the clinical trial?

American Genomics, LLCLead Sponsor
4 Previous Clinical Trials
314 Total Patients Enrolled
3 Trials studying Anesthesia, Local
300 Patients Enrolled for Anesthesia, Local
Martin Uram, MDStudy DirectorMedical Expert
4 Previous Clinical Trials
314 Total Patients Enrolled
3 Trials studying Anesthesia, Local
300 Patients Enrolled for Anesthesia, Local

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have an IOP between 7 and 30 mmHg.
You have a central corneal endothelial cell density of ≥1500 cells/mm2 at baseline.
You must provide written informed consent prior to any study-related procedures being performed.
You are male or a non-pregnant, non-lactating female.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.